Edico’s DRAGEN® Bio-IT Platform Delivers Faster, Streamlined Output
for Next-Generation Sequencing
SAN DIEGO--(BUSINESS WIRE)--May 15, 2018--
Illumina,
Inc. (NASDAQ: ILMN) today announced that it acquired Edico
Genome, the leading provider of data analysis acceleration solutions for
next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT
Platform (DRAGEN) uses field programmable gate array (FPGA) technology
in conjunction with proprietary software algorithms to reduce both data
footprint and time to results.
DRAGEN can be run on premise, in the cloud, or in a hybrid mode, and is
flexible and compatible for use with multiple cloud storage solutions
and analysis pipelines. Edico Genome has built a strong base of NGS
customers who have incorporated DRAGEN as a standard part of their
sequencing workflow.
“Our acquisition of Edico Genome is a big step toward realizing the
vision of reducing sequencing data acquisition and analysis to a
push-button, standardized process,” said Susan Tousi, Senior Vice
President of Product Development at Illumina. “We expect to build on the
solid foundation of DRAGEN to deliver a more streamlined and integrated
sample to answer experience for our customers.”
The DRAGEN platform complements Illumina’s sequencing portfolio and
enables customers to benefit from reduced investment in compute
infrastructure, and accelerated result times, to improve their overall
efficiency and to allow greater emphasis on interpretation and reporting.
“The scientific community should align around standards to maximize the
impact of genomics in health,” said Anthony Philippakis, MD, PhD, Chief
Data Officer of the Broad Institute of MIT and Harvard. “We are excited
to collaborate with Illumina on approaches and pipelines for the
analysis of NGS data. The Genome Analysis Toolkit (GATK) has been
adopted by a diverse set of researchers, and we look forward to
integrating these methods with Illumina sequencers to improve the
overall efficiency of data analysis—enabling the community to more
easily share and collaborate.”
“Thanks to Illumina, the ability to generate accurate and affordable
sequencing data is rapidly expanding the market and use cases for NGS.
As the scale of sequencing expands, decreasing the cost and time of
analysis will be important to fuel the clinical adoption of sequencing,”
said Pieter van Rooyen PhD, President and CEO of Edico Genome. “Our team
is invigorated at the prospect of joining Illumina to combine our
respective strengths to streamline and accelerate secondary analysis for
the genomics community.”
“We have had tremendous success at Rady’s for years using Edico’s DRAGEN
coupled with Illumina sequencers to accelerate the delivery of genomic
insights for critically ill newborns,” said Stephen F. Kingsmore, MD,
DSc, President and CEO of Rady Children’s Institute for Genomic
Medicine. “Our goal is to ensure that whole-genome sequencing is
available to every child who needs it. To do this, we need a rapid
workflow that can scale and ultimately be accessible to hospitals around
the world.”
For Research Use Only. Not for use in diagnostic procedures.
About Illumina
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding our expectations for future
improvements of our technology platform and the integration of Edico
Genome’s technology into our product portfolio. These forward-looking
statements are based on our expectations as of the date of this release
and may differ materially from actual future events or results. Among
the important factors that could cause actual results to differ
materially from those in any forward-looking statements are (i) our
ability to successfully integrate Edico Genome into our existing
operations and Edico Genome’s technology into our product portfolio;
(ii) our ability to further develop and commercialize our instruments
and consumables, services and applications, and expand the markets for
our technology platforms; (iii) our ability to manufacture robust
instrumentation and consumables; (iv) the future conduct and growth of
the business and the markets in which we operate; and (v) challenges
inherent in developing, manufacturing, and launching new products and
services, together with other factors detailed in our filings with
the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We
undertake no obligation, and do not intend, to update these
forward-looking statements, to review or confirm analysts’ expectations,
or to provide interim reports or updates on the progress of the current
quarter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180515005944/en/
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Jen
Carroll
858-882-6822
PR@illumina.com